Dysregulated Expression of Tensin ۲ and Components of the PI۳ Kinase/Akt Signaling Pathway in Human Thyroid Carcinoma

Publish Year: 1395
نوع سند: مقاله ژورنالی
زبان: English
View: 42

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MISJ-7-1_001

تاریخ نمایه سازی: 25 آبان 1402

Abstract:

Background: The phosphatidylinositol ۳-kinase/Akt signaling pathway is recognized as a key driver of cancer cell survival and proliferation, and is often contingent upon an impairment of expression/function of the PTEN tumor suppressor, a negative regulator of this pathway. In addition, the cytoskeletal signaling protein Tensin ۲ has also been implicated as a negative regulator of this pathway. However, the PI۳K pathway remains to be fully characterized in clinical thyroid carcinomas. The aim of this study is to determine the expression of components of the PI۳K pathway in neoplastic and normal tissue sections obtained from patients with thyroid carcinoma.Methods: Tissues from ۵۸ cases with thyroid carcinoma underwent immunohistochemistry for activated Akt (phosphorylated Akt, pAkt), Tensin ۲ and PTEN.Results: A total of ۱۰۰% of thyroid cancerous tissues were positive for pAkt staining compared to ۶۷.۹% of normal tissues. In contrast, ۴۶.۸% of cancer tissues were positive for Tensin ۲ compared to ۶۱.۷% of normal tissues. For PTEN, ۸۲.۸% of cancerous tissues and ۶۷.۲% of normal tissues stained positive for this protein. There were no associations between the expression levels of the molecules with the patients’ clinicopathological characteristics.Conclusion:We have found evidence for an enhanced activation of the PI۳K/Akt signaling pathway in clinical thyroid carcinoma tissues. This can be coupled with concomitant downregulation of Tensin ۲. Further work is required to determine the relative significance of PTEN expression versus its activity in thyroid carcinoma in order to determine its role in the observed increased Akt activity.

Authors

Nasrollah Erfani

Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Mohammad Javad Fattahi

Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Mohammad Hossein Dabbaghmanesh

Endocrinology and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Mohammad Mehrazmay

Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Ahmad Monabati

Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Akbar Rasekhi Kazerouni

Endocrinology and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Sassan Hafizi

Institute of Biomedical and Biomolecular Science, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK

Abbas Ghaderi

Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran